-
Home
- About PMI
-
Smoke-free approach
- What is harm reduction?
- Absence of combustion
- Nicotine
- The role of smoke-free products
- Tar
- Tobacco Regulation
Smoke-free approachOffering smoke-free alternatives to adult smokers is a sensible, complementary addition to existing tobacco control strategies.Read More -
Research
- Our Scientific Approach
- Our Findings
- PMI Publications Library
- Literature Reviews
- Independent Studies
- Expert Reports
- Investigator initiated studies (IIS)
- Latest PMI Science Booklet
- Facts and figures on our smoke-free future
ResearchPMI is committed to sharing results as the development and scientific assessment of smoke-free products advance.Read More -
Our Products
- Tobacco Heating System
- Oven Heating System
- MESH Vaping System
- Disposable Vaping System
- Oral Nicotine Pouches
- Nicotine salts product
Our ProductsPMI believes that offering a range of smoke-free alternatives is essential to ensure individual smokers are able to find a smoke-free product that they can fully switch to.Read More -
News & Events
- Scientific Update Magazine
- Open Science Events
- News
- Conferences Calendar
- Media Library
News & EventsRead our most recent articles and catch up on our latest events and conference presentations.Read More - Contact Us
Nicotine Pharmacokinetic and Pharmacodynamics Profile, Safety and Tolerability of P3L
A Single-center, Open-label, Ascending Nicotine Levels Study to Investigate the Nicotine Pharmacokinetic and Pharmacodynamics Profiles, Safety and Tolerability of P3L in Smoking Healthy Subjects in Relation to Nicorette® Inhalator
The purpose of this study is to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD, i.e., subjective effects) profiles, and the safety and tolerability of the nicotine-containing aerosol delivered by Platform 3 Liquid (P3L) system at three different nicotine levels in smoking healthy subjects in relation to Nicorette® inhalator.
Recruitment: Completed
Study Results: Available
Enrollment: 16
Study Type: Interventional
Other IDs: P3L-PK-01-NZ
Reduction in exposure to selected harmful and potentially harmful constituents approaching those observed upon smoking abstinence in smokers switching to the menthol Tobacco Heating System 2.2 for three months (Part 1)
Reduction in exposure to selected harmful and potentially harmful constituents approaching those observed upon smoking abstinence in smokers switching to the menthol Tobacco Heating System 2.2 for three months (Part 1)
Meta-analysis of the effects of smoking and smoking cessation on triglyceride levels
Smoking and apolipoprotein levels: A meta-analysis of published data
Effect of switching from cigarette smoking to the use of the tobacco heating system on periodontitis treatment outcome: Periodontal parameter results from a multicenter Japanese study
Effects of switching to a heat-not-burn tobacco product on biologically relevant biomarkers to assess a candidate Modified Risk Tobacco Product: A randomized trial
PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.
Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.